Previous 10 |
home / stock / zldpf / zldpf news
Press release - No. 2/2017 Zealand Pharma hosts Capital Market Day: Accelerating the late stage pipeline Four late stage programs with best-in-class potential and attractive risk profiles...
Company announcement - No. 6/2018 Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S. Glepaglutide is in development as a potential new treatment for patients with short bowel syndrome Oral presentation is based upon th...
Zealand Pharma ( OTCPK:ZLDPF ) is up 1% premarket, albeit on only 100 shares, on the heels of its announcement of positive early-stage data on GLP-2 analog glepaglutide. More news on: Zealand Pharma A/S, Healthcare stocks news, Stocks on the move, Read more ...
Company announcement - No. 5/2018 New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome (SBS) Zealand has completed a pharmacokinetic (PK) study with glepaglutide that confirms the potential for once-weekly dosing Zeal...
Company announcement - No. 4/2018 Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018 Zealand receives FDA a...
Company announcement - No. 3/2018 Zealand Pharma strengthens its Management by appointing Ivan Møller as SVP, Technical Development & Operations Copenhagen, Denmark, January 19, 2018 - Zealand Pharma A/S ("Zealand") announces the appointment of Ivan Møller to a new p...
Company announcement - No.1/ 2018 Zealand Pharma major shareholder announcement: Wellington Management Group LLP, U.S. Copenhagen, January 3, 2018 - Zealand Pharma announces that it has received information from Wellington Management Group LLP (Wellington Group Holdings LLP, Welling...
News, Short Squeeze, Breakout and More Instantly...
Zealand Pharma A/S Ord Company Name:
ZLDPF Stock Symbol:
OTCMKTS Market:
Zealand Pharma A/S Ord Website:
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE U...
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO T...
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CAN...